Recent stock market jitters have sparked fears that AI agents could spell doom for the contract research organization (CRO) industry, with some analysts worrying that pharmaceutical companies might bring clinical trials in-house and bypass CROs entirely. But industry insiders argue the panic may be overblown.
While it's true that AI-enabled trials could cut costs by 10 to 15%, the narrative of CROs becoming obsolete misses a crucial nuance. Rather than disappearing, tech-enabled organizations are evolving, adapting their models to integrate AI and remain competitive. The shake-up may not be a death knell, but a transformation.